alexa Nanoparticle-facilitated Intratumoral Delivery of Bcl-2/IGF-1R siRNAs and p53 Gene Synergistically Inhibits Tumor Growth in Immunocompetent Mice
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Nanoparticle-facilitated Intratumoral Delivery of Bcl-2/IGF-1R siRNAs and p53 Gene Synergistically Inhibits Tumor Growth in Immunocompetent Mice

Anil Philip Kunnath1, Nur Izyani Kamaruzman2 and Ezharul Hoque Chowdhury2*

1Faculty of Medicine and Health Sciences, IMU, Malaysia

2Advanced Engineering Platform and Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia

*Corresponding Author:
Ezharul Hoque Chowdhury
Advanced Engineering Platform and Jeffrey Cheah School of Medicine and Health Sciences
Monash University Malaysia
Tel: 603-5514-4978
Fax: 603-5514-6323
E-mail: [email protected]

Received Date: August 22, 2014; Accepted Date: October 22, 2014; Published Date: October 30, 2014

Citation: Kunnath AP, Kamaruzman NI, Chowdhury EH (2014) Nanoparticle-facilitated Intratumoral Delivery of Bcl-2/IGF-1R siRNAs and p53 Gene Synergistically Inhibits Tumor Growth in Immunocompetent Mice. J Nanomed Nanotechnol 6:278. doi:10.4172/2157-7439.1000278

Copyright: © 2014 Kunnath AP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Breast cancer, the leading cause of cancer-related deaths in women, is usually treated with surgery, radiation therapy, hormone-blocking/chemotherapy drugs, monoclonal antibodies or combinations of these approaches and agents depending on the cancer stage and the existence of specific receptors, with accompanying various adverse effects. Silencing of the genes responsible for cancer development and progression with small interfering RNA (siRNA) in combination with overexpression of the genes with tumor suppressing activities could be an attractive concept for precisely treating breast cancer with minimal side effects. However the short half-life in plasma due to nuclease-mediated degradation and renal clearance, and the inefficiency in penetrating the plasma membrane limit the applications of siRNA and DNA as therapeutic molecules. Recently, we have developed pH-sensitive carbonate apatite nano-carrier to efficiently deliver siRNA or DNA across the cell membrane facilitating them to escape endosomal acidic compartment and specifically cleave a cytoplasmic mRNA transcript or enable gene expression after nuclear translocation, respectively. Moreover, we demonstrated nanoparticle-accelerated delivery of the siRNAs targeting cyclin B1, PLC-gamma-2/ calmodulin1, HER2/ErbB2, ABCG2/ABCB1 and cROS1 mRNAs sensitizes cervical adenocarcinoma and breast cancer cells towards conventional anti-cancer drugs. Here, we report that co-delivery of the siRNAs targeting IGF-1R and Bcl-2 gene transcripts and the pasmid DNA containing p53 gene with the help of carbonate apatite nanoparticles synergistically induces inhibition of growth/proliferation of breast cancer cell lines as well as regression of the breast tumor induced in Balb/c mice. Additionally, concerted delivery of nanoparticle-associated IGF-1R/Bcl-2 siRNAs and p53 gene apparently slows down the growth of the established tumor in presence of doxorubicin or paclitaxel compared with the individual free drugs. Thus, the combination of IGF-1R/Bcl-2 knockdown and restoring of normal p53 function could be a highly promising approach that should be further investigated through pre-clinical trials to establish the therapeutic role of this combination therapy for breast cancer.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords